The revolutionary genome-editing technology CRISPR case started in January 2016, when the US patent office granted the University California’s an “interference” proceeding to investigate whether the CRISPR-Cas9 patent application the University California filed, but not issued, in May 2012 claimed… Continue Reading →
Gilead Sciences was recently ordered to pay $2.54 billion to Merck to resolve a long-running patent dispute concerning its blockbuster patent sellers Sovaldi (earning Gilead $19 billion) and Harvoni (earning Gilead $23 billion) for hepatitis C treatment. The patent dispute… Continue Reading →
© 2024 Dawn Ellmore Employment's Blog — Powered by WordPress
Theme by Anders Noren — Up ↑